CoChat

KDM4 Inhibition Targets Breast Cancer Stem–like Cells

Open access
Metzger, Eric, Stepputtis, Stella S., Strietz, Juliane, Preca, Bogdan-Tiberius, Urban, Sylvia, Willmann, Dominica, Allen, Anita, Zenk, Fides, Iovino, Nicola, Bronsert, Peter, Proske, Amelie, Follo, Marie, Boerries, Melanie, Stickeler, Elmar, Xu, Jiangchun, Wallace, Michael B., Stafford, Jeffrey A., Kanouni, Toufike, Maurer, Jochen, Schüle, Roland · 2017 · Cancer Research
Cited by 109

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Traditional treatments for breast cancer fail to address therapy-resistant cancer stem–like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here, we describe an orally available, selective and potent KDM4 inhibitor (QC6352) with unique preclinical characteristics. To assess the antitumor properties of QC6352, we established a method to isolate and propagate breast cancer stem–like cells (BCSC) from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. Limiting-dilution orthotopic xenografts of these BCSCs regenerated original patient tumor histology and gene expression. QC6352 blocked BCSC proliferation, sphere formation, and xenograft tumor formation. QC6352 also abrogated expression of EGFR, which drives the growth of therapy-resistant triple-negative breast cancer cells. Our findings validate a unique BCSC culture system for drug screening and offer preclinical proof of concept for KDM4 inhibition as a new strategy to treat triple-negative breast cancer. Cancer Res; 77(21); 5900–12. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-1754

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 109

Metadata

Authors
Metzger, E., Stepputtis, S. S., Strietz, J., Preca, B.-T., Urban, S., Willmann, D., Allen, A., Zenk, F., Iovino, N., Bronsert, P., Proske, A., Follo, M., Boerries, M., Stickeler, E., Xu, J., Wallace, M. B., Stafford, J. A., Kanouni, T., Maurer, J., & Schüle, R.
Venue
Cancer Research
Published
2017-10-31
Volume
77
Issue
21
Pages
5900-5912
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2752714009
Cited by
109
References
5
FWCI
3.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KDM4 Inhibition Targets Breast Cancer Stem–like Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-1754
The paper
Metzger, E., Stepputtis, S. S., Strietz, J., Preca, B.-T., Urban, S., Willmann, D., Allen, A., Zenk, F., Iovino, N., Bronsert, P., Proske, A., Follo, M., Boerries, M., Stickeler, E., Xu, J., Wallace, M. B., Stafford, J. A., Kanouni, T., Maurer, J., & Schüle, R. (2017). KDM4 Inhibition Targets Breast Cancer Stem–like Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-1754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.